Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes
The phase 3 ECHELON-3 study showed that adding brentuximab vedotin to lenalidomide and rituximab significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates (ORR) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who had received at least 2 prior lines of therapy. The triplet regimen resulted in a 47% reduction in the risk of disease progression or death and an ORR of 64.3% vs 41.5% with the doublet. The benefits were consistent across key subgroups, with manageable safety profiles.
Related Clinical Trials
Reference News
Adding brentuximab vedotin to lenalidomide and rituximab significantly improved OS, PFS, and ORR in relapsed/refractory DLBCL patients, with a 47% reduction in disease progression or death risk. The triplet regimen showed better outcomes across key subgroups and no new safety concerns.
The phase 3 ECHELON-3 study showed that adding brentuximab vedotin to lenalidomide and rituximab significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates (ORR) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who had received at least 2 prior lines of therapy. The triplet regimen resulted in a 47% reduction in the risk of disease progression or death and an ORR of 64.3% vs 41.5% with the doublet. The benefits were consistent across key subgroups, with manageable safety profiles.